.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Queensland Health
Baxter
US Army
Fuji
Julphar
Daiichi Sankyo
QuintilesIMS
Dow
Harvard Business School

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021313

« Back to Dashboard
NDA 021313 describes CLARINEX-D 12 HOUR, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug. Additional details are available on the CLARINEX-D 12 HOUR profile page.

The generic ingredient in CLARINEX-D 12 HOUR is desloratadine; pseudoephedrine sulfate. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the desloratadine; pseudoephedrine sulfate profile page.

Summary for 021313

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:4
Formulation / Manufacturing:see details

Pharmacology for NDA: 021313

Suppliers and Packaging for NDA: 021313

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLARINEX-D 12 HOUR
desloratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL 021313 NDA Merck Sharp & Dohme Corp. 0085-1322 0085-1322-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0085-1322-01)
CLARINEX-D 12 HOUR
desloratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL 021313 NDA Physicians Total Care, Inc. 54868-5708 54868-5708-0 10 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (54868-5708-0)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength2.5MG;120MG
Approval Date:Feb 1, 2006TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 7, 2020Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Feb 18, 2021Product Flag?YSubstance Flag?Delist Request?
Patented Use:ALLERGIC RHINITIS
Patent:► SubscribePatent Expiration:Jun 19, 2021Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 021313

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
CLARINEX-D 12 HOUR
desloratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL021313-001Feb 1, 2006► Subscribe► Subscribe
Merck Sharp Dohme
CLARINEX-D 12 HOUR
desloratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL021313-001Feb 1, 2006► Subscribe► Subscribe
Merck Sharp Dohme
CLARINEX-D 12 HOUR
desloratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL021313-001Feb 1, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chubb
US Department of Justice
Julphar
Cipla
Citi
UBS
Farmers Insurance
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot